Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Head & Neck 1

Conditions

Urinary Bladder Neoplasms 2Ovarian Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Head and Neck Neoplasms 1HER2-low Breast Cancer 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 69Bevacizumab 62Carboplatin 53pembrolizumab 46olaparib 32Specimen Handling 27Gemcitabine 27Cyclophosphamide 26Magnetic Resonance Spectroscopy 24liposomal doxorubicin 22Cisplatin 21niraparib 20Taxes 18Nivolumab 18fludarabine 17Topotecan 17Biopsy 17Doxorubicin 14Immunoglobulin G 12Fulvestrant 12Disulfides 12Oxaliplatin 10mirvetuximab soravtansine 9durvalumab 9aldesleukin 9Surveys and Questionnaires 9Ipilimumab 9Fluorouracil 9Blood Specimen Collection 9cemiplimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × RC48 antibody × 1 year × Clear all
NCT06003231 2026-06-01

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Seagen Inc.

Phase 2 Active not recruiting
120 enrolled
GynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT07285941 2025-12-16

Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment

Zhejiang Cancer Hospital

Phase 2 Recruiting
20 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡